HIGD1B Inhibitors
HIGD1B inhibitors such as Rotenone, Antimycin A, and Sodium azide disrupt different sites of the electron transport chain, thereby reducing the efficiency of oxidative phosphorylation and potentially affecting HIGD1B if its function is linked to electron transport or the mitochondrial membrane potential. Oligomycin directly inhibits ATP synthase, which could impact HIGD1B if it requires ATP for its activity. CCCP disrupts the proton gradient across the mitochondrial membrane, which could impact HIGD1B if its function is influenced by the membrane potential.
On the other hand, compounds like Atractyloside and Bongkrekic acid that target the adenine nucleotide transporter can affect the transport of ADP and ATP across the mitochondrial membrane, which could influence HIGD1B's function if it depends on the cellular ATP/ADP ratio. Methylene blue and 2-Deoxy-D-glucose can alter the redox state and availability of substrates for the TCA cycle, respectively, which can indirectly influence HIGD1B function by altering the metabolic state of the cell. Finally, Nicotinamide, by affecting NAD+ metabolism, can influence sirtuin and PARP activity, which could affect HIGD1B function if it is dependent on NAD+-related signaling. Metformin's impact on complex I can lead to changes in the cellular energy status, which could indirectly influence HIGD1B activity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rotenone | 83-79-4 | sc-203242 sc-203242A | 1 g 5 g | $89.00 $259.00 | 41 | |
Inhibits mitochondrial complex I, leading to reduced electron transport and potential indirect effects on HIGD1B if it is associated with this pathway. | ||||||
Antimycin A | 1397-94-0 | sc-202467 sc-202467A sc-202467B sc-202467C | 5 mg 10 mg 1 g 3 g | $55.00 $63.00 $1675.00 $4692.00 | 51 | |
Binds to complex III of the electron transport chain, disrupting electron flow, which could indirectly impact HIGD1B activity if it is part of the mitochondrial respiratory chain. | ||||||
Oligomycin | 1404-19-9 | sc-203342 sc-203342C | 10 mg 1 g | $149.00 $12495.00 | 18 | |
Inhibits ATP synthase (complex V), which could indirectly affect HIGD1B by altering mitochondrial ATP levels. | ||||||
Carbonyl Cyanide m-Chlorophenylhydrazone | 555-60-2 | sc-202984A sc-202984 sc-202984B | 100 mg 250 mg 500 mg | $77.00 $153.00 $240.00 | 8 | |
Uncouples oxidative phosphorylation, which can decrease mitochondrial membrane potential, potentially affecting HIGD1B if it is sensitive to membrane potential changes. | ||||||
Sodium azide | 26628-22-8 | sc-208393 sc-208393B sc-208393C sc-208393D sc-208393A | 25 g 250 g 1 kg 2.5 kg 100 g | $43.00 $155.00 $393.00 $862.00 $90.00 | 8 | |
Inhibits complex IV, which could reduce electron transport chain activity and indirectly affect HIGD1B function. | ||||||
Methylene blue | 61-73-4 | sc-215381B sc-215381 sc-215381A | 25 g 100 g 500 g | $43.00 $104.00 $328.00 | 3 | |
Acts as an alternative electron carrier in the ETC, which can bypass certain inhibition points and indirectly affect HIGD1B if it interacts with those points. | ||||||
Bongkrekic acid | 11076-19-0 | sc-205606 | 100 µg | $400.00 | 10 | |
Inhibits ANT by a different mechanism than atractyloside, possibly affecting HIGD1B if it is involved in adenine nucleotide transport. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $70.00 $215.00 | 26 | |
Inhibits glycolysis, which can decrease substrate availability for the TCA cycle and oxidative phosphorylation, indirectly affecting HIGD1B if it relies on these processes. | ||||||
Doxycycline Hyclate | 24390-14-5 | sc-204734B sc-204734 sc-204734A sc-204734C | 100 mg 1 g 5 g 25 g | $27.00 $50.00 $105.00 $194.00 | 25 | |
Has been shown to inhibit mitochondrial protein synthesis, which could affect HIGD1B if it is a mitochondrial-encoded protein. | ||||||
Nicotinamide | 98-92-0 | sc-208096 sc-208096A sc-208096B sc-208096C | 100 g 250 g 1 kg 5 kg | $44.00 $66.00 $204.00 $831.00 | 6 | |
Can inhibit sirtuins and PARP enzymes, affecting NAD+ metabolism and potentially impacting HIGD1B if it is regulated by NAD+ levels. | ||||||